Financings in Brief: Nanogen
This article was originally published in The Gray Sheet
Executive Summary
Nanogen: Completes $2.5 mil. round of venture capital financing, bringing the total raised this year to $9 mil. and the total raised since inception to $13 mil. The San Diego-based development-stage firm says its initial focus is on "rapid panel test opportunities in human DNA probe diagnostics." InterWest Partners of Menlo Park, California was a major investor in the current round, which is expected to fund R&D for the next 12-18 months. Separately, Nanogen says it "recently received a $2 mil., two-year grant from the U.S. Department of Commerce to fund development of an integrated microelectronic DNA diagnostic system"...
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.